Gsk (GSK) Operating Expenses (2009 - 2026)
Gsk (GSK) posted quarterly Operating Expenses of -$7.6 billion for Q2 2026, down 36.9% year-over-year from -$12.1 billion in Q2 2025, and down 48.01% quarter-over-quarter from -$5.1 billion in Q1 2026.
Gsk (GSK) Operating Expenses (2009 - 2026) Analysis & Trends
Gsk's Operating Expenses history runs 18 years deep, the most recent figure standing at -$7.6 billion for Q2 2026.
- In Q2 2026, Operating Expenses fell 36.9% year-over-year to -$7.6 billion; the TTM figure through Jun 2026 stood at -$40.1 billion (down 2.43% YoY), while the FY2025 annual figure was $21.9 billion, down 1.61% from the prior year.
- Operating Expenses for Q2 2026 stood at -$7.6 billion, down from -$5.1 billion in the prior quarter.
- The five-year high for Operating Expenses was -$3.4 billion in Q1 2022, with the low at -$22.4 billion in Q4 2024.
- The 5-year median for Operating Expenses is -$5.1 billion (2024), against an average of -$8.3 billion.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 39.35% in 2024, then grew 22.43% in 2025.
- Gsk's Operating Expenses stood at -$16.3 billion in 2022, then dropped by 19.16% to -$19.4 billion in 2023, then dropped by 15.39% to -$22.4 billion in 2024, then rose by 1.14% to -$22.1 billion in 2025, then jumped by 65.59% to -$7.6 billion in 2026.
- Business Quant data shows GSK's Operating Expenses at -$7.6 billion in Q2 2026, -$5.1 billion in Q1 2026, and -$22.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Bn |
| Mar 31, 2026 | -5.14 Bn |
| Dec 31, 2025 | -22.10 Bn |
| Sep 30, 2025 | -5.30 Bn |
| Jun 30, 2025 | -5.55 Bn |
| Mar 31, 2025 | -4.45 Bn |
| Dec 31, 2024 | -22.35 Bn |
| Sep 30, 2024 | -6.83 Bn |
| Jun 30, 2024 | -4.98 Bn |
| Mar 31, 2024 | -4.47 Bn |
| Dec 31, 2023 | -19.37 Bn |
| Sep 30, 2023 | -4.90 Bn |
| Jun 30, 2023 | -4.52 Bn |
| Mar 31, 2023 | -4.14 Bn |
| Dec 31, 2022 | -16.26 Bn |
| Sep 30, 2022 | -4.01 Bn |
| Jun 30, 2022 | -4.17 Bn |
| Mar 31, 2022 | -3.45 Bn |
| Dec 31, 2021 | -11.72 Bn |
| Sep 30, 2021 | -3.87 Bn |